Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study

Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study

Objectives The prognosis for adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is poor. Blinatumomab is a CD3/CD19-directed BiTE® (bispecific T-cell engager) molecule approved globally for the treatment of BCP-ALL in adults and children. This multicenter o...

Full description

Bibliographic Details
Main Authors: Hongsheng Zhou, Qingsong Yin, Jie Jin, Ting Liu, Zhen Cai, Bin Jiang, Dengju Li, Zimin Sun, Yan Li, Yanjuan He, Liping Ma, Sujun Gao, Jianda Hu, Aili He, Xin Du, Daihong Liu, Xiaohong Zhang, Xiaoyan Ke, Junling Zhuang, Yue Han, Xiaoqin Wang, Yuqi Chen, Paul Gordon, Dong Yu, Gerhard Zugmaier, Jianxiang Wang
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Hematology
Subjects:
Acute lymphoblastic leukemia
relapsed/refractory
BiTE® molecule
blinatumomab
Chinese adults
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2022.2111992

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2022.2111992

Similar Items